Systematic analysis of CD39, CD103, CD137, and PD‐1 as biomarkers for naturally occurring tumor antigen‐specific TILs

FS222, a CD137/PD-L1 tetravalent bispecific antibody exhibits low toxicity and anti-tumor activity in colorectal cancer models

(2020) Matthew A Lakins et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

(2020) Dmitriy Zamarin et al.   JOURNAL OF CLINICAL ONCOLOGY

CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement

(2020) Miguel Gaspar et al.   Cancer Immunology Research

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

(2019) Takahiro Kamada et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR

(2019) Wingchi Leung et al.   Cancer Immunology Research

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

(2019) Andrea Cossarizza et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

T Cell Dysfunction in Cancer

(2018) Daniela S. Thommen et al.   CANCER CELL

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

(2018) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells

(2018) Bertram Bengsch et al.   IMMUNITY

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

(2018) Thomas Duhen et al.   Nature Communications

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

(2017) Alice O. Kamphorst et al.   SCIENCE

Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation

(2017) Sivan Seliktar-Ofir et al.   Frontiers in Immunology

PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?

(2017) Sylvain Simon et al.   OncoImmunology

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

(2016) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression

(2016) Maria Parkhurst et al.   CLINICAL CANCER RESEARCH

Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis

(2015) Jacob H. Levine et al.   CELL

Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis

(2015) Yiting Geng et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

CD8+CD103+Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients

(2015) Fayçal Djenidi et al.   JOURNAL OF IMMUNOLOGY

Immune Checkpoint Inhibition: Therapeutic Implications in Epithelial Ovarian Cancer

(2015) Teresa Longoria et al.   Recent Patents on Anti-Cancer Drug Discovery

Overcoming T cell exhaustion in infection and cancer

(2015) Kristen E. Pauken et al.   TRENDS IN IMMUNOLOGY

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

(2014) Alena Gros et al.   JOURNAL OF CLINICAL INVESTIGATION

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

(2014) E. Tran et al.   SCIENCE

CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor

(2013) Q. Ye et al.   CLINICAL CANCER RESEARCH

viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia

(2013) El-ad David Amir et al.   NATURE BIOTECHNOLOGY

Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy

(2013) Jessica Ann Chacon et al.   PLoS One

Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes

(2012) Kevin M. Friedman et al.   JOURNAL OF IMMUNOTHERAPY

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

(2008) Naomi N. Hunder et al.   NEW ENGLAND JOURNAL OF MEDICINE